S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 186.35 CNY -2.73% Market Closed
Market Cap: 74.7B CNY
Have any thoughts about
Sichuan Biokin Pharmaceutical Co Ltd?
Write Note

Sichuan Biokin Pharmaceutical Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sichuan Biokin Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash & Cash Equivalents
ÂĄ391.7m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash & Cash Equivalents
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash & Cash Equivalents
ÂĄ8.8B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash & Cash Equivalents
ÂĄ22.3B
CAGR 3-Years
16%
CAGR 5-Years
41%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash & Cash Equivalents
ÂĄ14.1B
CAGR 3-Years
-9%
CAGR 5-Years
3%
CAGR 10-Years
24%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Cash & Cash Equivalents
ÂĄ1.5B
CAGR 3-Years
3%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
74.7B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
48.32 CNY
Overvaluation 74%
Intrinsic Value
Price
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
391.7m CNY

Based on the financial report for Dec 31, 2023, Sichuan Biokin Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 391.7m CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
105%

Over the last year, the Cash & Cash Equivalents growth was -61%. The average annual Cash & Cash Equivalents growth rates for Sichuan Biokin Pharmaceutical Co Ltd have been 105% over the past three years .

Back to Top